In this study, PEG-functionalized 5-FU loaded LPs were covalently conjugated with a specific antibody able to recognize and bind the FZD10 surface cell receptor, to create innovative immuno-LPs that could potentially be useful for targeted therapy of CRC. The gene discussed is FZD10; the disease is colorectal carcinoma.